

Electronic supplementary material

Methods

Analysis summarising exposure across the entire follow-up period

All patients who were prescribed insulin at any time during the follow-up period were included. The entry time was defined as 1 January 2002 for those receiving insulin on that date or date of first non-glargine insulin or insulin glargine thereafter. Subjects were classified as non-glargine insulin only if they did not use insulin glargine at any time in the study period, as non-glargine plus glargine insulin if they ever used insulin glargine in combination with another insulin, or as insulin glargine only if, when they were on insulin glargine, they did not use any other type of insulin. The follow-up for each person was continued to the first of the following: date of first cancer or cancer death, date of death from any cause, cessation of all insulin therapy, or 31 December 2005. Analysis was using Cox proportional hazards models adjustment for other covariates, as shown in the tables.